Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (75) 75
life sciences & biomedicine (69) 69
humans (56) 56
male (51) 51
female (45) 45
aged (36) 36
middle aged (34) 34
oncology (33) 33
adult (27) 27
chemotherapy (24) 24
lung cancer (24) 24
care and treatment (23) 23
lung neoplasms - drug therapy (22) 22
biological and medical sciences (19) 19
analysis (18) 18
cancer (17) 17
carcinoma, non-small-cell lung - drug therapy (16) 16
medical sciences (16) 16
cancer therapies (15) 15
lung cancer, non-small cell (15) 15
mutation (15) 15
treatment outcome (15) 15
tumors (14) 14
lung neoplasms - pathology (13) 13
metastasis (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
aged, 80 and over (11) 11
animals (11) 11
clinical trials (11) 11
medical research (11) 11
medicine & public health (11) 11
neoplasm staging (11) 11
patients (11) 11
hematology, oncology and palliative medicine (10) 10
prognosis (10) 10
research (10) 10
medical colleges (9) 9
antineoplastic agents - therapeutic use (8) 8
carcinoma, non-small-cell lung - genetics (8) 8
lung neoplasms - genetics (8) 8
lung neoplasms - mortality (8) 8
non-small cell lung carcinoma (8) 8
respiratory system (8) 8
carcinoma, non-small-cell lung - pathology (7) 7
immunotherapy (7) 7
japan (7) 7
medical prognosis (7) 7
platinum (7) 7
rats (7) 7
small cell lung carcinoma (7) 7
antineoplastic agents (6) 6
antineoplastic agents - adverse effects (6) 6
cell line, tumor (6) 6
etoposide (6) 6
follow-up studies (6) 6
genetic aspects (6) 6
health aspects (6) 6
immunohistochemistry (6) 6
lung neoplasms - metabolism (6) 6
medicine, experimental (6) 6
neurosciences & neurology (6) 6
toxicity (6) 6
abridged index medicus (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
apoptosis (5) 5
cell survival (5) 5
cisplatin - administration & dosage (5) 5
clinical neurology (5) 5
confidence intervals (5) 5
disease control (5) 5
disease-free survival (5) 5
etoposide - administration & dosage (5) 5
gene expression (5) 5
general & internal medicine (5) 5
internal medicine (5) 5
lung cancer, small cell (5) 5
lungs (5) 5
magnetic resonance imaging (5) 5
neurology (5) 5
oncology, experimental (5) 5
pharmacology & pharmacy (5) 5
product development (5) 5
rats, sprague-dawley (5) 5
small cell lung carcinoma - drug therapy (5) 5
studies (5) 5
survival (5) 5
tyrosine (5) 5
antitumor activity (4) 4
biomarkers (4) 4
carboplatin (4) 4
carboplatin - administration & dosage (4) 4
carboplatin - adverse effects (4) 4
carcinoma, non-small-cell lung - mortality (4) 4
college teachers (4) 4
cytotoxicity (4) 4
disease progression (4) 4
dose-response relationship, drug (4) 4
drug administration schedule (4) 4
epidermal growth factor (4) 4
epidermal growth factor receptors (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
by Seto, Takashi, MD and Kiura, Katsuyuki, Prof and Nishio, Makoto, MD and Nakagawa, Kazuhiko, Prof and Maemondo, Makoto, MD and Inoue, Akira, MD and Hida, Toyoaki, MD and Yamamoto, Nobuyuki, MD and Yoshioka, Hiroshige, MD and Harada, Masao, MD and Ohe, Yuichiro, MD and Nogami, Naoyuki, MD and Takeuchi, Kengo, MD and Shimada, Tadashi, MS and Tanaka, Tomohiro, MS and Tamura, Tomohide, Dr
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
by Seto, Takashi, MD and Kato, Terufumi, MD and Nishio, Makoto, MD and Goto, Koichi, MD and Atagi, Shinji, MD and Hosomi, Yukio, MD and Yamamoto, Noboru, MD and Hida, Toyoaki, MD and Maemondo, Makoto, MD and Nakagawa, Kazuhiko, Prof and Nagase, Seisuke, MD and Okamoto, Isamu, MD and Yamanaka, Takeharu, PhD and Tajima, Kosei, MSc and Harada, Ryosuke, BS and Fukuoka, Masahiro, MD and Yamamoto, Nobuyuki, Prof
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
by Takahashi, Toshiaki, MD and Yamanaka, Takeharu, Prof and Seto, Takashi, MD and Harada, Hideyuki, MD and Nokihara, Hiroshi, MD and Saka, Hideo, MD and Nishio, Makoto, MD and Kaneda, Hiroyasu, MD and Takayama, Koichi, MD and Ishimoto, Osamu, MD and Takeda, Koji, MD and Yoshioka, Hiroshige, MD and Tachihara, Motoko, MD and Sakai, Hiroshi, MD and Goto, Koichi, MD and Yamamoto, Nobuyuki, Prof
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 663 - 671
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Brain Neoplasms - diagnostic imaging | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Small Cell Lung Carcinoma - drug therapy | Small Cell Lung Carcinoma - secondary | Early Termination of Clinical Trials | Brain Neoplasms - secondary | Aged, 80 and over | Medical Futility | Adult | Female | Survival Rate | Cranial Irradiation - adverse effects | Brain Neoplasms - prevention & control | Small Cell Lung Carcinoma - prevention & control | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Small Cell Lung Carcinoma - diagnostic imaging | Watchful Waiting | Aged | Platinum Compounds - administration & dosage | Care and treatment | Chemotherapy | Lung cancer | Oncology, Experimental | Radiation | Clinical trials | Metastasis | Research | College teachers | Radiotherapy | Cancer | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
by Goss, Glenwood, Dr Prof and Tsai, Chun-Ming, Prof and Shepherd, Frances A, Prof and Bazhenova, Lyudmila, Prof and Lee, Jong Seok, MD and Chang, Gee-Chen, MD and Crino, Lucio, MD and Satouchi, Miyako, MD and Chu, Quincy, MD and Hida, Toyoaki, MD and Han, Ji-Youn, Prof and Juan, Oscar, MD and Dunphy, Frank, Prof and Nishio, Makoto, MD and Kang, Jin-Hyoung, MD and Majem, Margarita, MD and Mann, Helen, MSc and Cantarini, Mireille, MD and Ghiorghiu, Serban, MD and Mitsudomi, Tetsuya, Prof
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 12, pp. 1643 - 1652
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | ErbB Receptors - antagonists & inhibitors | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Piperazines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Tyrosine | Lung cancer, Non-small cell | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
by Shaw, Alice T, Dr and Kim, Tae Min, MD and Crinò, Lucio, Prof and Gridelli, Cesare, MD and Kiura, Katsuyuki, MD and Liu, Geoffrey, MD and Novello, Silvia, Prof and Bearz, Alessandra, MD and Gautschi, Oliver, MD and Mok, Tony, Prof and Nishio, Makoto, MD and Scagliotti, Giorgio, Prof and Spigel, David R, MD and Deudon, Stéphanie, PharmD and Zheng, Cheng, PhD and Pantano, Serafino, PhD and Urban, Patrick, MD and Massacesi, Cristian, MD and Viraswami-Appanna, Kalyanee, PhD and Felip, Enriqueta, MD
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 874 - 886
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Sulfones - therapeutic use | Pyrazoles - therapeutic use | gamma-Glutamyltransferase - blood | Humans | Middle Aged | Sulfones - adverse effects | Lung Neoplasms - pathology | Male | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Adult | Female | Pyridines - therapeutic use | Crizotinib | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Docetaxel | Disease Progression | Disease-Free Survival | Retreatment | Aspartate Aminotransferases - blood | Receptor Protein-Tyrosine Kinases - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - therapeutic use | Pyrimidines - therapeutic use | Gene Rearrangement | Pyrimidines - adverse effects | Carcinoma, Non-Small-Cell Lung - drug therapy | Platinum Compounds - administration & dosage | Neoplasm Staging | Care and treatment | Chemotherapy | Lymphomas | Research institutes | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
by Goto, Koichi, Dr and Ohe, Yuichiro, MD and Shibata, Taro, MSc and Seto, Takashi, MD and Takahashi, Toshiaki, MD and Nakagawa, Kazuhiko, Prof and Tanaka, Hiroshi, MD and Takeda, Koji, MD and Nishio, Makoto, MD and Mori, Kiyoshi, MD and Satouchi, Miyako, MD and Hida, Toyoaki, MD and Yoshimura, Naruo, MD and Kozuki, Toshiyuki, MD and Imamura, Fumio, MD and Kiura, Katsuyuki, Prof and Okamoto, Hiroaki, MD and Sawa, Toshiyuki, MD and Tamura, Tomohide, MD and JCOG0605 investigators and JCOG0605 Investigators
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Humans | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Etoposide - administration & dosage | Lung Neoplasms - pathology | Male | Survival Rate | Small Cell Lung Carcinoma - drug therapy | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Small Cell Lung Carcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Adult | Camptothecin - administration & dosage | Female | Aged | Neoplasm Staging | Camptothecin - analogs & derivatives | Medical colleges | Care and treatment | Relapse | Chemotherapy | Lung cancer | Etoposide | Respiratory agents | Product development | College teachers | Diseases | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
by Hida, Toyoaki, MD and Nokihara, Hiroshi, MD and Kondo, Masashi, MD and Kim, Young Hak, MD and Azuma, Koichi, MD and Seto, Takashi, MD and Takiguchi, Yuichi, Prof and Nishio, Makoto, MD and Yoshioka, Hiroshige, MD and Imamura, Fumio, MD and Hotta, Katsuyuki, Prof and Watanabe, Satoshi, MD and Goto, Koichi, MD and Satouchi, Miyako, MD and Kozuki, Toshiyuki, MD and Shukuya, Takehito, MD and Nakagawa, Kazuhiko, Prof and Mitsudomi, Tetsuya, Prof and Yamamoto, Nobuyuki, Prof and Asakawa, Takashi, PhD and Asabe, Ryoichi, MS and Tanaka, Tomohiro, MS and Tamura, Tomohide, Dr
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Metastasis | Kinases | Evidence-based medicine | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Vandetanib in patients with previously treated RET -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
by Yoh, Kiyotaka, Dr and Seto, Takashi, MD and Satouchi, Miyako, MD and Nishio, Makoto, MD and Yamamoto, Noboru, MD and Murakami, Haruyasu, MD and Nogami, Naoyuki, MD and Matsumoto, Shingo, MD and Kohno, Takashi, PhD and Tsuta, Koji, Prof and Tsuchihara, Katsuya, MD and Ishii, Genichiro, MD and Nomura, Shogo, MSc and Sato, Akihiro, MD and Ohtsu, Atsushi, MD and Ohe, Yuichiro, MD and Goto, Koichi, MD
The lancet respiratory medicine, ISSN 2213-2600, 2016, Volume 5, Issue 1, pp. 42 - 50
Pulmonary/Respiratory | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Piperidines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - administration & dosage | Disease-Free Survival | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Gene Order | Proto-Oncogene Proteins c-ret - genetics | Treatment outcome | Care and treatment | Vandetanib | Safety and security measures | Analysis | Dosage and administration | Lung cancer, Non-small cell | Clinical trials | Usage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study
by Kubota, Kaoru, Prof and Hida, Toyoaki, MD and Ishikura, Satoshi, MD and Mizusawa, Junki, MSc and Nishio, Makoto, MD and Kawahara, Masaaki, MD and Yokoyama, Akira, MD and Imamura, Fumio, MD and Takeda, Koji, MD and Negoro, Shunichi, MD and Harada, Masao, MD and Okamoto, Hiroaki, MD and Yamamoto, Nobuyuki, MD and Shinkai, Tetsu, MD and Sakai, Hiroshi, MD and Matsui, Kaoru, MD and Nakagawa, Kazuhiko, Prof and Shibata, Taro, MSc and Saijo, Nagahiro, Prof and Tamura, Tomohide, MD and on behalf of the Japan Clinical Oncology Group and Japan Clinical Oncology Grp and Japan Clinical Oncology Group
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 106 - 113
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - mortality | Humans | Middle Aged | Etoposide - administration & dosage | Lung Neoplasms - pathology | Male | Lung Neoplasms - therapy | Carcinoma, Small Cell - mortality | Chemoradiotherapy | Cisplatin - administration & dosage | Carcinoma, Small Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Camptothecin - administration & dosage | Dose Fractionation | Female | Aged | Carcinoma, Small Cell - pathology | Neoplasm Staging | Camptothecin - analogs & derivatives | Medical colleges | Care and treatment | Nuclear radiation | Lung cancer | Etoposide | College teachers | Radiotherapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
by Kiyotaka, YOH, MD and HOSOMI, Yukio, MD, PhD and KASAHARA, Kazuo, MD, PhD and YAMADA, Kazuhiko, MD, PhD and TAKAHASHI, Toshiaki, MD and YAMAMOTO, Nobuyuki, MD, PhD and NISHIO, Makoto, MD, PhD and Yuichiro, OHE, MD, PhD and Toshiko, KOUE, PhD and NAKAMURA, Takashi, MPH and ENATSU, Sotaro, MD, PhD and Pablo, LEE, MD and FERRY, David, PhD and TAMURA, Tomohide, MD and NAKAGAWA, Kazuhiko, MD, PhD
Lung cancer (Amsterdam, Netherlands), ISSN 0169-5002, 2016, Volume 99, pp. 186 - 193
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Non-small-cell lung cancer | Randomized phase II trial | Ramucirumab | Japan | Docetaxel | Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Platinum - administration & dosage | Taxoids - therapeutic use | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Risk Factors | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Taxoids - pharmacokinetics | Retreatment | Taxoids - administration & d